A

Amgen

Makes biotech medicines for serious illnesses

Healthcare Community Contracting Manager

Full-TimeUpdated on 10/22/2026
No salary listed
Senior, Expert
Bachelor's, Master's
Hyderabad, Telangana, India
In Person
Contract Management

About the job

Requirements
  • A Master's degree, or a Bachelor's degree and 8–12 years of biotech- or pharmaceutical-related business operations or supplier management experience.
  • Excellent computer and Microsoft Office skills.
  • Knowledge of Smartsheet.
  • Excellent writing skills and attention to detail.
  • Effective communication within and outside the department.
  • Good understanding of standard operating procedures and healthcare regulations.
  • Project management skills.
  • Ability to make decisions, work independently, prioritize and meet deadlines, and take initiative in a rapidly changing environment.
  • Experience with meeting planning and management.
  • Experience facilitating vendor contracts and contracts with members of the healthcare community.
  • Working knowledge of patient-engagement workflows, sponsorship and donation processes, C3, Cvent, TPS, supplier onboarding, and payment requirements.
  • Understanding of customer service principles as they apply to internal customers and external partners.
  • Vendor management and oversight experience.
  • Ability to process complex transactions end to end and engage business partners where appropriate.
  • Ability to identify and escalate business issues, identify process improvements, and manage multiple assignments and competing priorities, including a high volume of contract document requests.
  • Ability to interact with business partners to ensure compliance processes and standards are understood and followed.
  • Ability to apply established compliance processes, identify exceptions, and route matters to the appropriate HCC, Compliance, Legal, or country-level authority.
  • Ability to determine actions required to resolve issues and coordinate with other departments to ensure timely resolution.
  • Ability to interact with all levels of the organization and external stakeholders with a high level of customer service.
  • Strong time management and problem-solving skills.
Responsibilities
  • Lead review, drafting, and negotiation of contracts for members of the healthcare community, including complex agreements requiring knowledge of healthcare regulations, external healthcare engagements, business requirements, and legal compliance.
  • Operate independently with minimal supervision, engage business partners as appropriate, oversee timelines and escalations, and engage with senior leadership.
  • Participate in strategy sessions on execution of work between OUS and the US, and engage functional leads, Responsible Amgen Employees, HCC, Finance, Procurement, country partners, and external partners to keep requests moving.
  • Explain contract terms and positions to internal stakeholders.
  • Own external administrative communications, including process guidance, missing-information follow-up, contract execution, invoicing, and payment-status communications.
  • Track fee-for-service hours, contract expirations, aging requests, pending approvals, payment status, and required post-engagement documentation.
  • Communicate business risks to internal stakeholders and escalate as appropriate.
  • Manage sponsorship, membership, and donation workflows, including supplier-onboarding coordination, C3/TPS progression, budget-owner follow-up, payment tracking, and closeout.
  • Ensure submissions are complete, timely, and routed correctly.
  • Coordinate tangible-benefit execution, including deadlines, registrations, asset collection, proof of benefit, TPS closeout, and reporting.
  • Collaborate with legal, sourcing, accounts payable, and other relevant teams to streamline financial processes and resolve issues or discrepancies; maintain effective communication and working relationships.
  • Ensure compliance with internal controls, policies, and regulations, and develop and enforce policies and procedures related to contracting and payment operations.
  • Maintain complete, compliant, audit-ready documentation through submission, contracting, payment, and closeout; participate in audits and assist with compliance-related activities.
  • Contribute to strategic initiatives to optimize contracting and payment processes.
  • Maintain relationships by communicating and collaborating with Law, Regulatory, Global Meeting Management, Worldwide Compliance and Business Ethics groups, and International Healthcare Compliance.
  • Review proposed arrangements through Amgen’s healthcare compliance operations system of record, C3, and support Amgen staff with related questions and C3 system support.
  • Draft contracts and amendments, resolve contract negotiation or management issues, and drive contracts to execution.
  • Build effective working relationships with Responsible Amgen Employees, professional participants, advocacy organizations, and internal operational partners.
  • Manage payment inquiries from healthcare-community members, Responsible Amgen Employees, and service providers, including further review, research, and triage as appropriate.
  • Maintain oversight of the contracts and payments team providing support to Amgen staff.
  • Perform other duties as assigned.
Desired Qualifications
  • Law or paralegal background.
  • Strong external customer service background.
  • Managerial experience directly managing people, and/or leadership experience leading teams, projects, or programs or directing resource allocation.
  • Data analytics skills and experience with analytics software such as Spotfire, Tableau, or Smartsheet; document management applications such as Veeva; portfolio planning tools; and financial systems such as Planisware, SAP, or Microsoft Project.
  • Knowledge of advocacy functionality at a large biotechnology organization.
  • Strong understanding of healthcare regulations, contract terms, and payment processes.
  • Demonstrated leadership skills and ability to effectively manage projects and teams.
  • Excellent communication, negotiation, and relationship-building skills.
  • Proficiency in contract management software and financial systems.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.